Daan Gene Co., Ltd. (SHE:002030)
China · Delayed Price · Currency is CNY 6.88
-0.42 (-5.75%)
May 12, 2026, 3:04 PM CST
Daan Gene Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 737.96 | 757.66 | 843.75 | 1,173 | 12,040 | 7,615 |
Other Revenue | - | - | 9.27 | 8 | 6.08 | 48.84 |
| 737.96 | 757.66 | 853.02 | 1,181 | 12,046 | 7,664 | |
Revenue Growth (YoY) | -10.42% | -11.18% | -27.77% | -90.20% | 57.17% | 43.49% |
Cost of Revenue | 498.99 | 512.17 | 629.58 | 801.12 | 3,615 | 1,963 |
Gross Profit | 238.97 | 245.49 | 223.44 | 379.78 | 8,431 | 5,701 |
Selling, General & Admin | 381.4 | 381.26 | 333.32 | 300.68 | 1,246 | 1,124 |
Research & Development | 158.07 | 186.34 | 225.67 | 302.33 | 702.4 | 508.8 |
Other Operating Expenses | -19.3 | -24.95 | -18.22 | -8.56 | 101.03 | 36.34 |
Operating Expenses | 520.17 | 542.65 | 936.47 | 735.82 | 2,347 | 1,800 |
Operating Income | -281.2 | -297.16 | -713.02 | -356.04 | 6,084 | 3,901 |
Interest Expense | - | - | -9.74 | -10.04 | -13.94 | -9.35 |
Interest & Investment Income | 49.43 | 49.43 | 69.37 | 83.1 | 370.86 | 266.7 |
Currency Exchange Gain (Loss) | - | - | 5.85 | 2.28 | 25.72 | -1.85 |
Other Non Operating Income (Expenses) | -51.13 | -82.31 | -4.07 | -12.77 | -22.07 | -12.56 |
EBT Excluding Unusual Items | -282.9 | -330.05 | -651.62 | -293.48 | 6,445 | 4,144 |
Gain (Loss) on Sale of Investments | -238.54 | 4.57 | -429.58 | 409.44 | 73.97 | -83.78 |
Gain (Loss) on Sale of Assets | 5.49 | 5.48 | 9.1 | -3.04 | -1.15 | 0.11 |
Asset Writedown | -434.71 | -436.99 | -10.65 | -59.48 | -256.35 | -15 |
Legal Settlements | - | - | 0.07 | 1.42 | 0.46 | - |
Other Unusual Items | - | - | 11.52 | 58.67 | 57.22 | 74.44 |
Pretax Income | -950.66 | -756.99 | -1,071 | 113.54 | 6,319 | 4,120 |
Income Tax Expense | -20.68 | 23.53 | -132.05 | 41.8 | 891.38 | 501.59 |
Earnings From Continuing Operations | -929.98 | -780.52 | -939.11 | 71.73 | 5,428 | 3,618 |
Net Income to Company | -929.98 | -780.52 | -939.11 | 71.73 | 5,428 | 3,618 |
Minority Interest in Earnings | 34.52 | 36.14 | 13.94 | 32.93 | -15.22 | -0.3 |
Net Income | -895.46 | -744.38 | -925.17 | 104.66 | 5,412 | 3,618 |
Net Income to Common | -895.46 | -744.38 | -925.17 | 104.66 | 5,412 | 3,618 |
Net Income Growth | - | - | - | -98.07% | 49.59% | 47.74% |
Shares Outstanding (Basic) | 1,424 | 1,404 | 1,402 | 1,495 | 1,403 | 1,403 |
Shares Outstanding (Diluted) | 1,424 | 1,404 | 1,402 | 1,495 | 1,403 | 1,403 |
Shares Change (YoY) | 2.97% | 0.19% | -6.25% | 6.53% | - | - |
EPS (Basic) | -0.63 | -0.53 | -0.66 | 0.07 | 3.86 | 2.58 |
EPS (Diluted) | -0.63 | -0.53 | -0.66 | 0.07 | 3.86 | 2.58 |
EPS Growth | - | - | - | -98.19% | 49.59% | 47.74% |
Free Cash Flow | 95.49 | 80.49 | 125.92 | 207.34 | 2,652 | 2,646 |
Free Cash Flow Per Share | 0.07 | 0.06 | 0.09 | 0.14 | 1.89 | 1.89 |
Dividend Per Share | - | - | - | 0.015 | 1.750 | 1.110 |
Dividend Growth | - | - | - | -99.14% | 57.66% | 222.86% |
Gross Margin | 32.38% | 32.40% | 26.19% | 32.16% | 69.99% | 74.39% |
Operating Margin | -38.10% | -39.22% | -83.59% | -30.15% | 50.51% | 50.90% |
Profit Margin | -121.34% | -98.25% | -108.46% | 8.86% | 44.93% | 47.21% |
Free Cash Flow Margin | 12.94% | 10.62% | 14.76% | 17.56% | 22.02% | 34.52% |
EBITDA | -2.13 | -6.15 | -374.26 | -11.82 | 6,347 | 4,093 |
EBITDA Margin | -0.29% | -0.81% | -43.88% | -1.00% | 52.69% | 53.41% |
D&A For EBITDA | 279.07 | 291.01 | 338.76 | 344.23 | 262.88 | 192.02 |
EBIT | -281.2 | -297.16 | -713.02 | -356.04 | 6,084 | 3,901 |
EBIT Margin | -38.10% | -39.22% | -83.59% | -30.15% | 50.51% | 50.90% |
Effective Tax Rate | - | - | - | 36.82% | 14.11% | 12.17% |
Revenue as Reported | - | - | 853.02 | 1,181 | 12,046 | 7,664 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.